An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation

• Main Authors: Mirja Harms (Author), Monica M.W. Habib (Author), Simona Nemska (Author), Antonella Nicolò (Author), Andrea Gilg (Author), Nico Preising (Author), Pandian Sokkar (Author), Sara Carmignani (Author), Martina Raasholm (Author), Gilbert Weidinger (Author), Gönül Kizilsavas (Author), Manfred Wagner (Author), Ludger Ständker (Author), Ashraf H. Abadi (Author), Hassan Jumaa (Author), Frank Kirchhoff (Author), Nelly Frossard (Author), Elsa Sanchez-Garcia (Author), Jan Münch (Author)
• Format: Book
• Published: Elsevier, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist and inverse agonist of CXCR4 and is a promising compound for t...